TCGA-AR-A5QM-01A-11R-A27Q-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.450
- MYOGENESIS+0.360
- IL6_JAK_STAT3_SIGNALING+0.350
- NOTCH_SIGNALING+0.340
- COAGULATION+0.330
- ESTROGEN_RESPONSE_EARLY+0.330
- INTERFERON_ALPHA_RESPONSE+0.330
- INFLAMMATORY_RESPONSE+0.320
- ANGIOGENESIS+0.310
- INTERFERON_GAMMA_RESPONSE+0.290
Top 10 suppressed
- MYC_TARGETS_V1-0.570
- E2F_TARGETS-0.560
- G2M_CHECKPOINT-0.490
- MTORC1_SIGNALING-0.430
- PROTEIN_SECRETION-0.430
- MYC_TARGETS_V2-0.400
- MITOTIC_SPINDLE-0.370
- UNFOLDED_PROTEIN_RESPONSE-0.350
- OXIDATIVE_PHOSPHORYLATION-0.270
- ANDROGEN_RESPONSE-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NPQJ20KX | pilocytic astrocytoma | — | 0.916 |
| 2 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.904 |
| 3 | c5e09ad2-1f0b-4ea3-9565-a1664f1bb468 | — | — | 0.904 |
| 4 | TCGA-GM-A3XN-01A-12R-A22U-07 | — | A | 0.899 |
| 5 | BS_5P3CZQV8 | Neurofibroma | — | 0.897 |
| 6 | SRR2689710 | — | — | 0.894 |
| 7 | sclcA055A_S52.txt | — | cohortMD2 | 0.891 |
| 8 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.889 |
| 9 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.888 |
| 10 | TCGA-AC-A3BB-01A-21R-A19W-07 | — | A | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.290 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.110 | Idelalisib | — uncovered |